$VANI

Vivani Medical, Inc. (VANI): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Vivani Medical, Inc. (VANI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 7 ex101_1.htm EXHIBIT 10.1 Exhibit 10.1 VIVANI MEDICAL, INC. AMENDED AND RESTATED 2022 OMNIBUS INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Amended and Restated Vivani Medical, Inc. 2022 Omnibus Incentive Plan (the “Plan”)

Original reporting
Published Jun 30, 2026, 12:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$VANI
Neutral
low confidence
Mentioned
$VANI
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VANINeutralLow
01

Why it matters

Without the specific names and terms of the departures/elections/appointments, the excerpt mainly signals standard corporate governance and equity-compensation framework updates rather than an operational or financial catalyst.

02

Market read

This is a governance/compensation disclosure; it may matter for longer-term sentiment around leadership and dilution expectations, but the excerpt lacks actionable specifics.

03

What to watch

Traders should verify the full 8-K for the specific director/officer changes and any non-routine compensation triggers; those details could raise materiality beyond the plan boilerplate shown.

Relevance 6/10Novelty 3/10Timing: as of the 8-K filing date (June 30, 2026)

Background

The filing references Item 5.02/5.07 on director/officer changes and submission of matters to a security-holder vote, with an exhibit describing the company’s amended and restated 2022 omnibus incentive plan.

Company-level read

Ticker impact

$VANINeutralLow confidence
Context

Vivani Medical filed an 8-K for director/officer departures and elections plus compensatory arrangements under its incentive plan.

Expected impact

Likely limited near-term impact unless the missing 8-K details specify material leadership changes or unusual compensation terms.

Evidence & confidence

The provided text is largely incentive-plan boilerplate; the excerpt does not include the specific director/officer names, terms, or any quantified compensation changes.

Market effects

No clear sector read-across from the excerpt; it is company-specific governance/compensation documentation.

None indicated.

None indicated.

Counterpoint

This may be routine annual/periodic governance and equity-compensation housekeeping with minimal trading significance.

Key entities

  • Vivani Medical, Inc.

    Subject of the SEC 8-K; governance and compensatory arrangements are referenced under Item 5.02.

Related articles

$VANIMed

Vivani Medical, Inc. (VANI): Results of Operations and Financial Condition

Vivani Medical, Inc. (VANI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight mana

$VANIMed

Vivani Flat on Hookup with Novo

Vivani Medical (NASDAQ: VANI) said it signed an agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139 semaglutide implant using Vivani’s NanoPortal platform for chronic weight management. Vivani noted no exclusivity. It plans to start a Phase 1 first-in-human study mid-2026, using Wegovy as comparator, to support a Phase 2 dose-ranging study.

$VANIMedAI 8/10

Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

Vivani Medical (Nasdaq: VANI) said its subsidiary Cortigent will merge into ClearOne (Nasdaq: CLRO), with Cortigent becoming a wholly owned ClearOne unit. ClearOne plans a concurrent $10–15M financing via an S-1. Vivani will receive 12.5M ClearOne shares for 59.4%–67.5% ownership; ClearOne will rename to Cortigent Holdings (CRGT), expected to close Q3 2026.

$VANIMedAI 8/10

Vivani Medical, Inc.: Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

Vivani Medical (Nasdaq: VANI) said its subsidiary Cortigent will merge into ClearOne (Nasdaq: CLRO) via a definitive agreement, making Cortigent a wholly owned ClearOne unit. ClearOne plans a concurrent $10m–$15m financing. Vivani will receive 12.5m ClearOne shares and own 59.4%–67.5%; the combined company will trade as CRGT, expected to close Q3 2026.

$ELVRMed

Elevra Lithium Ltd (ASX:ELV) Corporate Presentation - Outlines Growth Strategy for North American Lithium Platform

Elevra Lithium Ltd (ASX:ELV) outlined its growth strategy for North American Lithium (NAL) in Quebec, targeting 373,000 tonnes of spodumene concentrate annually. FY26 production was 197,967 tonnes, with revenue of US$202 million. The company plans a three-stage expansion, with initial capital expenditure of US$271 million. FY27 production guidance is 198,000 to 210,000 tonnes.